-transparent.png){kind=logo}
Sixteen previously treated patients received AZQ in a phase II study to test therapeutic efficacy in refractory small cell lung cancer. The dose and schedule of AZQ was 20 mg/m2 day 1 and 8, with treatments repeated every 28 days. No objective responses were noted among 16 evaluable patients. Myelosuppression was the major toxicity. AZQ does not appear to have antitumor activity in patients with previously treated small cell carcinoma.
Related Publications
J Z Fuks, and
J Aisner, and
D A Van Echo, and
M Levitt, and
D C Ihde, and
D Carney, and
P H Wiernik
May 1983,
Cancer treatment reports,
J Z Fuks, and
J Aisner, and
D A Van Echo, and
M Levitt, and
D C Ihde, and
D Carney, and
P H Wiernik
January 1983,
Cancer treatment reports,
J Z Fuks, and
J Aisner, and
D A Van Echo, and
M Levitt, and
D C Ihde, and
D Carney, and
P H Wiernik
December 1982,
Cancer treatment reports,
J Z Fuks, and
J Aisner, and
D A Van Echo, and
M Levitt, and
D C Ihde, and
D Carney, and
P H Wiernik
October 1982,
American journal of clinical oncology,
J Z Fuks, and
J Aisner, and
D A Van Echo, and
M Levitt, and
D C Ihde, and
D Carney, and
P H Wiernik
December 1982,
Cancer treatment reports,
J Z Fuks, and
J Aisner, and
D A Van Echo, and
M Levitt, and
D C Ihde, and
D Carney, and
P H Wiernik
October 1982,
Cancer treatment reports,
J Z Fuks, and
J Aisner, and
D A Van Echo, and
M Levitt, and
D C Ihde, and
D Carney, and
P H Wiernik
January 1981,
Cancer treatment reports,
J Z Fuks, and
J Aisner, and
D A Van Echo, and
M Levitt, and
D C Ihde, and
D Carney, and
P H Wiernik
January 2016,
PloS one,
J Z Fuks, and
J Aisner, and
D A Van Echo, and
M Levitt, and
D C Ihde, and
D Carney, and
P H Wiernik
June 1984,
Cancer treatment reports,
J Z Fuks, and
J Aisner, and
D A Van Echo, and
M Levitt, and
D C Ihde, and
D Carney, and
P H Wiernik
February 1986,
American journal of clinical oncology,
